2021

• Tyligand Bioscience Aquired ONA-XR (Onapristone sustained relese) right of development and commercialization in Greater China
• Tyligand Bioscience Receives IND Clearance from U.S. FDA for TSN084, a Multi-kinase Inhibitor to Address Tumor Resistance to Targeted Therapies